Emnéus pursued her academic career at Lund University, Sweden and was recruited as a Professor at DTU Nanotech in 2007 where she now leads the LOC strategic field and Bioanalytics group. She has in the past coordinated 7 EU projects and currently has two Marie Sklodowska Curie ITN projects in H2020, one of which she is coordinating (Training4CRM). She has served as an evaluator and expert panel member of . Swedish and Norwegian Research Councils, EU FP7 environment program and is since 2012 a Life Science panel member for ERC starting grant. She has vast experience of development and application of biosensors and 2D and 3D Lab-on-a-chip devices. Her main research interest is focused on bioanalytical systems (enzymes, antibodies and cells) using multi-parameter detection (optical and electrochemical), and organ-on-a chip system and 3D scaffolds for tissue engineering.
Damien has over 17 years product development experience in the medtech sector having held R&D engineering roles at . Bard, Boston Scientific and most recently Creganna-Tactx Medical. During this time, he has worked on the development and commercialisation of a wide range of minimally invasive devices for the cardiovascular and interventional radiology markets, including myocardial injection catheters, self-expanding and drug eluting stents, balloon angioplasty catheters, vena cava filters, thrombectomy catheters, AAA stent-grafts and introducer sheaths. Damien’s main professional interests and expertise lie in the areas of concept development, design control, and product commercialisation. A native of Galway, Damien graduated from Mechanical Engineering at NUI Galway and was subsequently awarded a scholarship to complete a research master’s in composite materials. In 2008, he obtained an MBA from Cairnes Business School at NUI Galway which strengthened his interest in innovation and entrepreneurship within the medtech industry. As a BioInnovate fellow, Damien’s goal is to capitalise on the world-class medical device development capability within Ireland to develop marketable technologies for improving user experiences and patient outcomes.